SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (“BSD” or “Company”) (NASDAQ: BSDM) today reported presentation of a clinical study being conducted at Duke University on the use of hyperthermia, delivered using the BSD-2000 Hyperthermia System, combined with chemotherapy to treat bladder cancer patients who have failed standard therapy. The clinical study abstract, titled “Pilot Study of External Hyperthermia and Intravesical Mitomycin-C to Treat Recurrent Bladder Cancer after Resection and Standard Adjuvant Therapy,” was presented by Zeljko Vujaskovic, MD, PhD, Duke University Medical Center (Duke), at the annual American Society of Clinical Oncology (ASCO) meeting, held in Chicago, Illinois, on June 4 to June 8, 2010.
